SAM
NBIX icon

Storebrand Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Storebrand Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19M Buy
7,071
+6,490
+1,117% +$963K ﹤0.01% 642
2026
Q1 		$76.5K Sell
581
-3,805
-87% -$505K ﹤0.01% 731
2025
Q4 		$622K Hold
4,386
– – ﹤0.01% 673
2025
Q3 		$616K Buy
4,386
+224
+5% +$30.4K ﹤0.01% 676
2025
Q2 		$523K Sell
4,162
-923
-18% -$106K ﹤0.01% 686
2025
Q1 		$562K Sell
5,085
-30,202
-86% -$3.83M ﹤0.01% 696
2024
Q4 		$4.82M Sell
35,287
-61,765
-64% -$7.64M 0.01% 504
2024
Q3 		$11.2M Buy
97,052
+18,575
+24% +$2.55M 0.04% 374
2024
Q2 		$10.8M Buy
78,477
+2,230
+3% +$306K 0.04% 379
2024
Q1 		$10.5M Sell
76,247
-888
-1% -$121K 0.04% 380
2023
Q4 		$10.2M Sell
77,135
-29,738
-28% -$3.42M 0.04% 379
2023
Q3 		$12M Sell
106,873
-653
-0.6% -$68.8K 0.06% 331
2023
Q2 		$10.1M Sell
107,526
-25,487
-19% -$2.49M 0.05% 367
2023
Q1 		$13.5M Buy
133,013
+30,936
+30% +$3.22M 0.07% 312
2022
Q4 		$12.2M Buy
102,077
+95,286
+1,403% +$11.2M 0.07% 320
2022
Q3 		$721K Hold
6,791
– – ﹤0.01% 688
2022
Q2 		$662K Hold
6,791
– – ﹤0.01% 703
2022
Q1 		$637K Sell
6,791
-482
-7% -$40.8K ﹤0.01% 712
2021
Q4 		$619K Hold
7,273
– – ﹤0.01% 733
2021
Q3 		$698K Sell
7,273
-3,980
-35% -$376K ﹤0.01% 740
2021
Q2 		$1.1M Hold
11,253
– – 0.01% 706
2021
Q1 		$1.09M Sell
11,253
-16,000
-59% -$1.68M 0.01% 700
2020
Q4 		$2.61M Sell
27,253
-4,311
-14% -$416K 0.02% 598
2020
Q3 		$3.04M Buy
31,564
+21,000
+199% +$2.43M 0.02% 539
2020
Q2 		$1.29M Buy
10,564
+5,741
+119% +$634K 0.01% 631
2020
Q1 		$417K Buy
+4,823
New +$472K ﹤0.01% 675

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Storebrand Asset Management's NBIX Position: Q2 2026 in Review

Storebrand Asset Management increased its Neurocrine Biosciences (NBIX) stake by 1,117% in Q2 2026, buying an estimated $963K and bringing the position to 7,071 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #642.

Storebrand Asset Management first reported a position in NBIX in Q1 2020 and has held it in 26 quarters since. The position peaked at $13.5M in Q1 2023. 733 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Storebrand Asset Management held 7,071 shares of Neurocrine Biosciences worth $1.19M as of Q2 2026.
  • Storebrand Asset Management bought 6,490 Neurocrine Biosciences shares in Q2 2026, an estimated $963K.
  • Neurocrine Biosciences made up ﹤0.01% of Storebrand Asset Management's portfolio in Q2 2026, its #642 holding.
  • Storebrand Asset Management first reported a position in Neurocrine Biosciences in Q1 2020 and has held it in 26 quarters since.
  • Storebrand Asset Management's Neurocrine Biosciences position peaked at $13.5M in Q1 2023.
  • 733 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Storebrand Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.